Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.

Naoki HorikawaKaoru AbikoNoriomi MatsumuraTsukasa BabaJunzo HamanishiKen YamaguchiRyusuke MurakamiMana TakiMasayo UkitaYuko HosoeMasafumi KoshiyamaIkuo KonishiMasaki Mandai

Published in: British journal of cancer (2020)

The anti-VEGF therapy induces tumour hypoxia and GM-CSF expression, which recruits MDSCs and inhibits tumour immunity. Targeting the GM-CSF could help overcome the anti-VEGF therapy resistance in ovarian cancers.

Keyphrases

endothelial cells
vascular endothelial growth factor
poor prognosis
cell therapy
high glucose
oxidative stress
bone marrow
cerebrospinal fluid
replacement therapy
smoking cessation